Sixty seconds on . . . asthma injections
BMJ 2024; 387 doi: https://doi.org/10.1136/bmj.q2690 (Published 02 December 2024) Cite this as: BMJ 2024;387:q2690
- Jacqui Wise
- Kent
What’s new?
Research published in the journal Lancet Respiratory Medicine found that an injection of a monoclonal antibody called benralizumab significantly reduced asthma attacks and chronic obstructive pulmonary disease (COPD) exacerbations when compared with the current standard treatment of prednisolone.1
This isn’t a wheeze, is it?
It’s no joke—and, as it’s the first new treatment for asthma and COPD attacks in 50 years, people are excited. Mona Bafadhel, a professor from the King’s Centre for Lung Health and lead investigator of the trial, said that the treatment could “be a game changer for people with asthma and COPD.”
Tell me more—I need to inhale this information
Patients with acute …
Log in
Log in using your username and password
Log in through your institution
Subscribe from £184 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£50 / $60/ €56 (excludes VAT)
You can download a PDF version for your personal record.